OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
No benefit from adding MTX to ustekinumab	513
Bimekizumab effective across the axSpA spectrum	442
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	335
Genome-wide mutagenesis reported in systemic sclerosis	295
The role of the patient in rheumatology	263
Osteoarthritis as a systemic disease	222
Biological and clinical roles of IL-18 in inflammatory diseases	210
Rheumatic diseases on the rise	187
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	175
A role for TGFβ and EBV in MIS-C pathogenesis	174
Towards better management of sterile bone inflammation	164
New drug formulation reduces bone loss	158
To choose or not? The value of discrete-choice experiments in rheumatology	156
Urchin-like nanoparticles for miRNA therapy of OA	152
The value of comparative efficacy studies in informing rheumatology guidelines	147
2021 ACR guideline for JIA reflects changes in practice	147
The 2022 ACR vaccination guideline: a call-to-action	147
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	141
Inflammation across tissues: can shared cell biology help design smarter trials?	140
Down syndrome: insights into autoimmune mechanisms	132
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	132
MIS-C: myths have been debunked, but mysteries remain	127
Appraising the evolving landscape of protease inhibition in osteoarthritis	125
FOXP3 splice variant is associated with autoimmune disease	124
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	122

Low-dose glucocorticoids benefit seniors with RA	118
Guiding ILD management in systemic autoimmune rheumatic diseases	115
Co-trimoxazole reduces mortality in anti-MDA5-DM	115
Immune reset and immune retune: approaching cure?	110
Fibroblast TGFβ drives treatment-refractory RA	109
COPA syndrome spans multiple organs but is defined by STING in the lung	106
Wnt-induced IGF1 drives OA	105
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	105
A direct link between SARS-CoV-2 and bone loss	104
Author Correction: Proposals for the rheumatological use of JAK inhibitors	100
Calprotectin tracks tocilizumab-treated RA	99
Fumarate drives interferon release in systemic sclerosis monocytes	98
S100A4 inhibition targets fibrosis in SSc	96
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	92
Pain in systemic lupus erythematosus: emerging insights and paradigms	92
Low back pain is a growing concern	88
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	87
Rheumatology in the digital health era: status quo and quo vadis?	85
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	82
Rheumatic diseases and metabolism: where centre and periphery meet	79
Targeting the IVD clock to halt degeneration	76
Which DMARD for ICI-associated arthritis?	73
sCD13 role in arthritis mediated via bradykinin receptor	73
Macrophage-coated nanocarriers for gouty arthritis	72
Cell-free DNA fragmentation signatures link cancer and autoimmunity	71
Erosive cargo from synovial fibroblasts	67
A path towards personalized medicine for autoinflammatory and related diseases	65
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	65
Phase III trial of telitacicept in SLE	65
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	65
Insights into IVDD pathogenesis in 2024	64
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	63
CAR T cells induce drug-free SLE remission	61